| Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. | |
| | |
MedLine Citation:
|
PMID: 19121410 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pulmonary arterial hypertension (PAH) has evolved from an untreatable condition to a disease for which several classes of drugs have now been approved, including various prostanoids, endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Because the pathogenesis of pulmonary hypertension is increasingly understood, various new substances are now under clinical investigation, including serotonin antagonists, vasoactive intestinal peptide, stimulators of soluble guanylate cyclase and tyrosine kinase inhibitors. Several of these compounds hold promise for the future therapy of PAH, especially as regression of pulmonary vascular remodeling appears to become a realistic possibility with the combination of established and novel treatments. |
| | |
Authors:
|
Karen M Olsson; Marius M Hoeper |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2009-01-20 |
Journal Detail:
|
Title: Drug discovery today Volume: 14 ISSN: 1878-5832 ISO Abbreviation: Drug Discov. Today Publication Date: 2009 Mar |
Date Detail:
|
Created Date: 2009-03-16 Completed Date: 2009-05-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9604391 Medline TA: Drug Discov Today Country: England |
Other Details:
|
Languages: eng Pagination: 284-90 Citation Subset: IM |
Affiliation:
|
Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Clinical Trials as Topic Drug Delivery Systems* Drug Therapy, Combination Humans Hypertension, Pulmonary / drug therapy*, physiopathology Pulmonary Artery / pathology |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitor...
Next Document: G-protein-coupled receptor-focused drug discovery using a target class platform approach.